Research ExplorerPublicationsRifamycin derivatives active against pathogenic rapidly-grow...

Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria

Standard

Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria. / Combrink, Keith D; Ramos, Andrea Ramirez; Spring, Stephanie; Schmidl, Sebastian; Elizondo, Kira; Morin, Petronilo; De Jesus, Bryant; Maurer, Florian P.

In: BIOORG MED CHEM LETT, Vol. 29, No. 16, 15.08.2019, p. 2112-2115.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Combrink, KD, Ramos, AR, Spring, S, Schmidl, S, Elizondo, K, Morin, P, De Jesus, B & Maurer, FP 2019, 'Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria', BIOORG MED CHEM LETT, vol. 29, no. 16, pp. 2112-2115. https://doi.org/10.1016/j.bmcl.2019.07.001

APA

Combrink, K. D., Ramos, A. R., Spring, S., Schmidl, S., Elizondo, K., Morin, P., De Jesus, B., & Maurer, F. P. (2019). Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria. BIOORG MED CHEM LETT, 29(16), 2112-2115. https://doi.org/10.1016/j.bmcl.2019.07.001

Vancouver

Combrink KD, Ramos AR, Spring S, Schmidl S, Elizondo K, Morin P et al. Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria. BIOORG MED CHEM LETT. 2019 Aug 15;29(16):2112-2115. https://doi.org/10.1016/j.bmcl.2019.07.001

Bibtex

@article{04ef1effa618405d8622d7e8cf3e4d15,
title = "Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria",
abstract = "Infections due to rapidly growing mycobacteria (RGM), and in particular the RGM species Mycobacterium abscessus (Mab), are very difficult to treat and reports on novel therapeutic options are scarce. A hallmark of all pathogenic RGM species is their resistance to the four first-line drugs used to treat infections with Mycobacterium tuberculosis including rifampicin. This study demonstrates that modification of the rifampicin scaffold can restore rifampicin activity against the three most commonly isolated pathogenic RGM species including Mab. We also note that the structure-activity relationship for Mab is different as compared to the non-pathogenic RGM species Mycobacterium smegmatis.",
author = "Combrink, {Keith D} and Ramos, {Andrea Ramirez} and Stephanie Spring and Sebastian Schmidl and Kira Elizondo and Petronilo Morin and {De Jesus}, Bryant and Maurer, {Florian P}",
note = "Copyright {\textcopyright} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = aug,
day = "15",
doi = "10.1016/j.bmcl.2019.07.001",
language = "English",
volume = "29",
pages = "2112--2115",
number = "16",

}

RIS

TY - JOUR

T1 - Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria

AU - Combrink, Keith D

AU - Ramos, Andrea Ramirez

AU - Spring, Stephanie

AU - Schmidl, Sebastian

AU - Elizondo, Kira

AU - Morin, Petronilo

AU - De Jesus, Bryant

AU - Maurer, Florian P

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/8/15

Y1 - 2019/8/15

N2 - Infections due to rapidly growing mycobacteria (RGM), and in particular the RGM species Mycobacterium abscessus (Mab), are very difficult to treat and reports on novel therapeutic options are scarce. A hallmark of all pathogenic RGM species is their resistance to the four first-line drugs used to treat infections with Mycobacterium tuberculosis including rifampicin. This study demonstrates that modification of the rifampicin scaffold can restore rifampicin activity against the three most commonly isolated pathogenic RGM species including Mab. We also note that the structure-activity relationship for Mab is different as compared to the non-pathogenic RGM species Mycobacterium smegmatis.

AB - Infections due to rapidly growing mycobacteria (RGM), and in particular the RGM species Mycobacterium abscessus (Mab), are very difficult to treat and reports on novel therapeutic options are scarce. A hallmark of all pathogenic RGM species is their resistance to the four first-line drugs used to treat infections with Mycobacterium tuberculosis including rifampicin. This study demonstrates that modification of the rifampicin scaffold can restore rifampicin activity against the three most commonly isolated pathogenic RGM species including Mab. We also note that the structure-activity relationship for Mab is different as compared to the non-pathogenic RGM species Mycobacterium smegmatis.

U2 - 10.1016/j.bmcl.2019.07.001

DO - 10.1016/j.bmcl.2019.07.001

M3 - SCORING: Journal article

C2 - 31281018

VL - 29

SP - 2112

EP - 2115

IS - 16

ER -